Anti-LASV glycoprotein complex [25.10C], Human IgG1, Fc Silent™, kappa

Catalogue Number: AB05115-10.3-ABA

Manufacturer:	Vector Laboratories, Inc (ABA)
Type:	Recombinant Monoclonal
Alias:	Lassa virus glycoprotein complex; GPC; Pre-glycoprotein polyprotein GP complex; Pre-GP-C; Stable signal peptide; SSP; Glycoprotein G1; GP1; Glycoprotein G2; GP2
Shipping Condition:	Blue Ice
Unit(s):	100 ug
Host name:	Human
Clone:	25.10C
Isotype:	IgG1
Immunogen:	The original antibody was generated from the B cells of a human survivor of Lassa fever.
Application:	ELISA, EM, NT, InVitroA

Overview
Datasheets

Additional Text

Purification

Purified

UniProt ID

P08669

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.

Gene ID

956585

Gene Name

LASVsSgp2

Short Description

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Application Notes

The original antibody (human IgG1) was generated and confirmed to specifically recognize the Lassa virus (LASV) glycoprotein complex (GPC) via ELISA. In vitro, this antibody demonstrated potent neutralizing activity against all four LASV lineages, as shown in pseudovirus assays and Plaque Reduction Neutralization Test (PRNT) (Robinson et al., 2016; PMID: 27161536). A Fab variant of this antibody was generated and tested. Cryo-EM provided insights into the neutralization mechanism-the antibody's heavy chain primarily contacts residues in GP1 (loop 225-235), essential for binding to the endosomal receptor LAMP1, while the light chain anchors to the GP2 fusion loop. By binding to these epitope sites, the antibody inhibits viral entry by blocking the interaction between LASV GP and LAMP1, preventing membrane fusion and infection. BLI characterization revealed high binding affinity, with apparent KD values of 3.52 nM, 36.1 pM, and <1.00 pM for LASV lineage I (LI) GP, the LI-R95M-GP variant, and LASV lineage IV (LIV) GP, respectively (Buck et al., 2022; PMID: 35730904). This antibody's neutralizing activity was unaffected by any of the seven glycan-knockout mutants (N99, N109, N119, N167, N224, N390, N395) on LASV GPC, as shown in the heat map of IC50 fold-changes. The Fab version of this antibody formed a stable complex with a GPCysRRLL-LPETG-1NOG trimer, as visualized by NS-EM 2D-average images and 3D-maps, confirming that it recognizes the fully cleaved, prefusion GPC trimer with native SKI-1/S1P cleavage and mammalian glycosylation (Li et al., 2022; PMID: 36288283). The original version of this antibody was used as a positive control in a pseudovirus neutralization assay alongside polyclonal antibodies generated in non-human primates and demonstrated near-complete neutralization of wild-type LASV pseudovirus (ppLASV, Josiah strain) at a low concentration (1 µg/ml) (Enriquez et al., 2025; PMID: 40168843).

AB05115-10.3 Datasheet

Price

£430.00

-

Quantity
Unit Size

Find out about delivery